That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...

Vertex secured FDA approval for JOURNAVX, a non-opioid pain treatment, marking a significant advancement in pain management. The company reached a reimbursement agreement with NHS England for ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment. It’s the first new class ...

It's the first new class of pain treatment approved in more than 20 years, Vertex says. Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday's market open after the Food and Drug ...

A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative ...

Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of $460. Published first on TheFly – the ultimate source ...

On Wednesday, the 40-year-old British driver went for a spin during Day 2 of testing on the Spanish circuit, resulting in a minor crash. SkySports reported there were no injuries to Hamilton and ...

Lewis Hamilton took to the Circuit de Barcelona-Catalunya on Tuesday in a Ferrari SF-23 from the 2023 season as part of Ferrari's second Testing of Previous Cars session. This followed nearly a ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ...

Vertex has built an empire in cystic fibrosis (CF) treatment, recently crowning its dominance with Alyftrek's approval last month. This latest CF drug adds even more firepower to a franchise ...

Notably, Vertex Pharmaceuticals (NASDAQ: VRTX), which focuses on developing treatments for rare diseases, has significantly outpaced both its biotechnology peers and the S&P 500 since early 2022.